Though Amgen's new cancer drug Kyprolis passed earlier clinical trials, it did not achieve success in a late-stage trials. An important aspect in cancer treatment is for how long can a patient live with the disease without concerning for its progress.

During a phase 2 trial, 23% of the multiple myeloma patients responded positively to Kyprolis even though it failed at two previous treatments. Myeloma is a type of blood cancer that develops in the bone marrow of a person.

Amgen published a report of a trial few days back called ASPIRE that studied Kyprolis and revlimid's (from Celgene) working in combination with a corticosteroid that can improve the expectancy of life by almost nine months.

Latest study by Amgen called FOCUS concentrated on the importance of overall survival. It included patients whose multiple myeloma had relapsed and deteriorated regardless of at least three prior therapies. Kyprolis unfortunately gave no better results as compared to the control group that was administered low-dose dexamethasone or another corticosteroid in combination with cyclophosphamide.

Amgen in a statement said that it hopes that positive results announced earlier this month derived from a separate study of Kyprolis in patients who are at the beginning stage of the disease will be enough to support regulatory submission around the world.

Sanford Bernstein analyst Geoffrey Porges said, "The negative results commercialization of this drug in earlier lines of myeloma, as well as other indications raise questions about the future development".

RBC Capital Markets analyst Michael Yee said it was expected that the trial would fail but occurrence of side effects related to Kidney is not a matter of concern as the trial had severely ill patients. Shares of Amgen were down by 2.1% at $124.5 on Wednesday.